Zafgen, Inc. (NASDAQ:ZFGN) released its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.49) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.52) by $0.03, Bloomberg Earnings reports. During the same period in the prior year, the business posted ($0.55) EPS.

Zafgen (NASDAQ ZFGN) traded down 4.1559% during midday trading on Thursday, hitting $3.2587. The company had a trading volume of 83,211 shares. Zafgen has a 1-year low of $2.89 and a 1-year high of $5.46. The firm’s market capitalization is $89.20 million. The company has a 50 day moving average price of $3.53 and a 200 day moving average price of $4.09.

Several analysts have issued reports on the company. ValuEngine raised Zafgen from a “strong sell” rating to a “sell” rating in a report on Thursday, July 6th. Zacks Investment Research lowered Zafgen from a “buy” rating to a “hold” rating in a report on Thursday, July 13th. Finally, Roth Capital assumed coverage on Zafgen in a report on Thursday, April 20th. They set a “buy” rating and a $9.00 price target for the company. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and one has issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $24.33.

ILLEGAL ACTIVITY NOTICE: “Zafgen, Inc. (NASDAQ:ZFGN) Announces Quarterly Earnings Results” was first posted by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another website, it was stolen and reposted in violation of US & international copyright laws. The legal version of this report can be viewed at

In other news, insider Dennis D. Kim acquired 10,000 shares of the stock in a transaction that occurred on Tuesday, July 11th. The shares were bought at an average cost of $3.39 per share, for a total transaction of $33,900.00. Following the acquisition, the insider now owns 21,443 shares in the company, valued at approximately $72,691.77. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 21.20% of the company’s stock.

Zafgen Company Profile

Zafgen, Inc is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.

Earnings History for Zafgen (NASDAQ:ZFGN)

Receive News & Ratings for Zafgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen Inc. and related companies with's FREE daily email newsletter.